Pan Tumor Webinar Series: Immunotherapy Updates in GEJ and CRC

Immunotherapies are rapidly changing the standard of care for patients with cancer. Checkpoint inhibitors constitute a highly active area of research with numerous clinical trials underway to investigate the efficacy and safety of these agents, including many in combination trials with other immunotherapies, targeted therapies, chemotherapies, and/or radiation therapies. Results from these trials are reported on an almost daily basis, leaving busy clinicians scrambling to assess available evidence and identify the most promising approaches to treat their patients with advanced cancers. “Immunotherapy Updates in GEJ and CRC,” will review new data and treatment indications for immunotherapies in gastrointestinal and colorectal cancers. This session will also discuss the incorporation of new data into treatment decision-making and review approaches to address potential adverse events with therapy.

Featured Speakers:

Yelena Y. Janjigian, MD
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

Michael J. Overman, MD
Professor of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Topics of Interest:

• Current indications in gastric cancer/gastroesophageal junction (GEJ) cancer
• Clinical trials in gastric/GEJ cancers
• Clinical updates in management of MSI-H colorectal cancer (CRC)
• Evolving approaches for MSS-CRC
  

Learning Objectives:

• Discuss changes to the treatment algorithm and the issuance of updated guideline directed strategies to better incorporate immunotherapies into clinical practice
• Evaluate the latest safety and efficacy data across checkpoint inhibitors for cancer treatment
• Review new indications that expand the selection of treatment options
  Integrate mitigation and management strategies for adverse events related to immunotherapies

Keywords:

gastrointestinal cancers, gastric cancer, gastroesophageal junction cancer, GEJ cancer, esophageal cancer, colorectal cancer, CRC, micro-satellite stable colorectal cancer, MSS-CRC, microsatellite instability high colorectal cancer, MSI-H CRC, mismatch repair deficient colorectal cancer, dMMR CRC, non-small cell lung cancer, NSCLC, small cell lung cancer, SCLC, immunotherapy for cancer, biomarker selection, Immune-related adverse events, irAEs, checkpoint inhibitors, immune checkpoint inhibitors, antibody drug conjugates, ADCs, CAR-T therapy, tumor-infiltrating lymphocyte therapy, TIL therapy